PDF herunterladen
Semin Respir Crit Care Med 2013; 34(01): 003-016
DOI: 10.1055/s-0032-1333467
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Global Epidemiology of Tuberculosis

Philippe Glaziou
1   Stop TB Department (STB), HIV/AIDS, TB, Malaria and Neglected Tropical Diseases Cluster (HTM), World Health Organization, Geneva, Switzerland
,
Dennis Falzon
1   Stop TB Department (STB), HIV/AIDS, TB, Malaria and Neglected Tropical Diseases Cluster (HTM), World Health Organization, Geneva, Switzerland
,
Katherine Floyd
1   Stop TB Department (STB), HIV/AIDS, TB, Malaria and Neglected Tropical Diseases Cluster (HTM), World Health Organization, Geneva, Switzerland
,
Mario Raviglione
1   Stop TB Department (STB), HIV/AIDS, TB, Malaria and Neglected Tropical Diseases Cluster (HTM), World Health Organization, Geneva, Switzerland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
04. März 2013 (online)

   Lizenzen und Reprints

Abstract

With 1.4 million deaths in 2011 and 8.7 million new cases, tuberculosis (TB) disease remains a global scourge. Global targets for reductions in the epidemiological burden of TB have been set for 2015 and 2050 within the context of the Millennium Development Goals (MDGs) and by the Stop TB Partnership. Achieving these targets is the focus of national and international efforts in TB control, and demonstrating whether or not they are achieved is of major importance to guide future and sustainable investments.

This paper discusses the methods used to estimate the global burden of TB; estimates of incidence, prevalence, and mortality for 2011, combined with assessment of progress toward the 2015 targets for reductions in these indicators based on trends since 1990 and projections up to 2015; trends in TB notifications and in the implementation of the Stop TB Strategy; and prospects for elimination of TB by 2050.

Keywords

tuberculosis - epidemiology - burden - incidence - prevalence - mortality
 

  • References

  • 1 WHO. Global tuberculosis report 2012. Geneva, Switzerland: WHO; 2012
    Google Scholar
  • 2 WHO, ed. The Global Burden of Disease: 2004 Update. Geneva, Switzerland: World Health Organization; 2008
    Google Scholar
  • 3 Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367 (9524) 1747-1757
    CrossrefPubMedGoogle Scholar
  • 4 Miller TL, McNabb SJ, Hilsenrath P, Pasipanodya J, Weis SE. Personal and societal health quality lost to tuberculosis. PLoS ONE 2009; 4 (4) e5080
    CrossrefPubMedGoogle Scholar
  • 5 Zumla A, Mwaba P, Huggett J, Kapata N, Chanda D, Grange J. Reflections on the white plague. Lancet Infect Dis 2009; 9 (3) 197-202
    CrossrefPubMedGoogle Scholar
  • 6 Lienhardt C, Glaziou P, Uplekar M, Lönnroth K, Getahun H, Raviglione M. Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol 2012; 10 (6) 407-416
    PubMedGoogle Scholar
  • 7 Murray CJ, DeJonghe E, Chum HJ, Nyangulu DS, Salomao A, Styblo K. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991; 338 (8778) 1305-1308
    CrossrefPubMedGoogle Scholar
  • 8 Dye C, Floyd K. Tuberculosis. In: Jamison DT, Breman JG, Measham AR, , et al, eds. Disease Control Priorities in Developing Countries. Washington, DC: Oxford University Press; 2006: 289-309
    CrossrefGoogle Scholar
  • 9 Dye C, Bassili A, Bierrenbach AL , et al. Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis 2008; 8 (4) 233-243
    CrossrefPubMedGoogle Scholar
  • 10 Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006; 367 (9514) 952-955
    CrossrefPubMedGoogle Scholar
  • 11 Korenromp EL, Glaziou P, Fitzpatrick C , et al. Implementing the global plan to stop TB, 2011–2015—optimizing allocations and the Global Fund's contribution: a scenario projections study. PLoS ONE 2012; 7 (6) e38816
    CrossrefPubMedGoogle Scholar
  • 12 Raviglione MC. The Global Plan to Stop TB, 2006–2015. Int J Tuberc Lung Dis 2006; 10 (3) 238-239
    PubMedGoogle Scholar
  • 13 Raviglione MC. The new Stop TB Strategy and the Global Plan to Stop TB, 2006–2015. Bull World Health Organ 2007; 85 (5) 327
    CrossrefPubMedGoogle Scholar
  • 14 Van Hest NA, Story A, Grant AD, Antoine D, Crofts JP, Watson JM. Record-linkage and capture-recapture analysis to estimate the incidence and completeness of reporting of tuberculosis in England 1999–2002. Epidemiol Infec 2008; 136 (12) 1606-1616
    CrossrefPubMedGoogle Scholar
  • 15 Bierrenbach AL, Stevens AP, Gomes AB , et al. [Impact on tuberculosis incidence rates of removal of repeat notification records.]. Rev Saude Publica 2007; 41 (Suppl. 01) 67-76
    CrossrefPubMedGoogle Scholar
  • 16 Dye C, Ottmani S, Laasri L, Bencheikh N. The decline of tuberculosis epidemics under chemotherapy: a case study in Morocco. Int J Tuberc Lung Dis 2007; 11 (11) 1225-1231
    PubMedGoogle Scholar
  • 17 Mansoer JSS, Scheele S, Floyd K, Dye C, Sitienei J, Williams B. New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya. Bull World Health Organ 2009; 87 (3) 186-192 , 192A–192B
    CrossrefPubMedGoogle Scholar
  • 18 Botha E, den Boon S, Lawrence KA , et al. From suspect to patient: tuberculosis diagnosis and treatment initiation in health facilities in South Africa. Int J Tuberc Lung Dis 2008; 12 (8) 936-941
    PubMedGoogle Scholar
  • 19 Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282 (7) 677-686
    CrossrefPubMedGoogle Scholar
  • 20 Uplekar M, Pathania V, Raviglione M. Private practitioners and public health: weak links in tuberculosis control. Lancet 2001; 358 (9285) 912-916
    CrossrefPubMedGoogle Scholar
  • 21 Meintjes G, Schoeman H, Morroni C, Wilson D, Maartens G. Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: a cross-sectional study. BMC Infect Dis 2008; 8: 72
    CrossrefPubMedGoogle Scholar
  • 22 Véron LJ, Blanc LJ, Suchi M, Raviglione MC. DOTS expansion: will we reach the 2005 targets?. Int J Tuberc Lung Dis 2004; 8 (1) 139-146
    PubMedGoogle Scholar
  • 23 Baussano I, Bugiani M, Gregori D , et al. Undetected burden of tuberculosis in a low-prevalence area. Int J Tuberc Lung Dis 2006; 10 (4) 415-421
    PubMedGoogle Scholar
  • 24 Borgdorff MW, Glynn JR, Vynnycky E. Using capture-recapture methods to study recent transmission of tuberculosis. Int J Epidemiol 2004; 33 (4) 905-906 , author reply 907
    CrossrefPubMedGoogle Scholar
  • 25 Cailhol J, Che D, Jarlier V, Decludt B, Robert J. Incidence of tuberculous meningitis in France, 2000: a capture-recapture analysis. Int J Tuberc Lung Dis 2005; 9 (7) 803-808
    PubMedGoogle Scholar
  • 26 Crofts JP, Pebody R, Grant A, Watson JM, Abubakar I. Estimating tuberculosis case mortality in England and Wales, 2001–2002. Int J Tuberc Lung Dis 2008; 12 (3) 308-313
    PubMedGoogle Scholar
  • 27 WHO, ed. Tuberculosis Prevalence Surveys: A Handbook. Geneva, Switzerland: WHO; 2011
    Google Scholar
  • 28 Glaziou P, van der Werf MJ, Onozaki I , et al. Tuberculosis prevalence surveys: rationale and cost. Int J Tuberc Lung Dis 2008; 12 (9) 1003-1008
    PubMedGoogle Scholar
  • 29 Soemantri S, Senewe FP, Tjandrarini DH , et al. Three-fold reduction in the prevalence of tuberculosis over 25 years in Indonesia. Int J Tuberc Lung Dis 2007; 11 (4) 398-404
    PubMedGoogle Scholar
  • 30 Dye C, Fengzeng Z, Scheele S, Williams B. Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. Int J Epidemiol 2000; 29 (3) 558-564
    CrossrefPubMedGoogle Scholar
  • 31 Tupasi TE, Radhakrishna S, Rivera AB , et al. The 1997 Nationwide Tuberculosis Prevalence Survey in the Philippines. Int J Tuberc Lung Dis 1999; 3 (6) 471-477
    PubMedGoogle Scholar
  • 32 Hong YP, Kim SJ, Lew WJ, Lee EK, Han YC. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis 1998; 2 (1) 27-36
    PubMedGoogle Scholar
  • 33 Korenromp EL, Bierrenbach AL, Williams BG, Dye C. The measurement and estimation of tuberculosis mortality. Int J Tuberc Lung Dis 2009; 13 (3) 283-303
    PubMedGoogle Scholar
  • 34 WHO. Guidelines for Surveillance of Drug Resistance in Tuberculosis. Geneva, Switzerland: WHO; 2009
    Google Scholar
  • 35 Riley RL. The contagiosity of tuberculosis. Schweiz Med Wochenschr 1983; 113 (3) 75-79
    PubMedGoogle Scholar
  • 36 WHO. Tuberculosis Fact Sheet. Geneva, Switzerland: WHO; 2012
    Google Scholar
  • 37 Borgdorff MW, Sebek M, Geskus RB, Kremer K, Kalisvaart N, van Soolingen D. The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol 2011; 40 (4) 964-970
    CrossrefPubMedGoogle Scholar
  • 38 Vynnycky E, Fine PE. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol 2000; 152 (3) 247-263
    CrossrefPubMedGoogle Scholar
  • 39 Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS ONE 2011; 6 (4) e17601
    CrossrefPubMedGoogle Scholar
  • 40 Straetemans M, Glaziou P, Bierrenbach AL, Sismanidis C, van der Werf MJ. Assessing tuberculosis case fatality ratio: a meta-analysis. PLoS ONE 2011; 6 (6) e20755
    CrossrefPubMedGoogle Scholar
  • 41 Shilova MV, Dye C. The resurgence of tuberculosis in Russia. Philos Trans R Soc Lond B Biol Sci 2001; 356 (1411) 1069-1075
    PubMedGoogle Scholar
  • 42 Glaziou P, Floyd K, Korenromp EL , et al. Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bull World Health Organ 2011; 89 (8) 573-582
    CrossrefPubMedGoogle Scholar
  • 43 Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS ONE 2010; 5 (12) e15241
    CrossrefPubMedGoogle Scholar
  • 44 Williams BG, Granich R, De Cock KM, Glaziou P, Sharma A, Dye C. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci USA 2010; 107 (45) 19485-19489
    CrossrefPubMedGoogle Scholar
  • 45 Corbett EL, Charalambous S, Moloi VM , et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med 2004; 170 (6) 673-679
    CrossrefPubMedGoogle Scholar
  • 46 Ottmani SE, Uplekar MW. Gender and TB: pointers from routine records and reports. Int J Tuberc Lung Dis 2008; 12 (7) 827-828
    PubMedGoogle Scholar
  • 47 Thorson A, Long NH, Larsson LO. Chest X-ray findings in relation to gender and symptoms: a study of patients with smear positive tuberculosis in Vietnam. Scand J Infect Dis 2007; 39 (1) 33-37
    CrossrefPubMedGoogle Scholar
  • 48 Borgdorff MW, Nagelkerke NJ, Dye C, Nunn P. Gender and tuberculosis: a comparison of prevalence surveys with notification data to explore sex differences in case detection. Int J Tuberc Lung Dis 2000; 4 (2) 123-132
    PubMedGoogle Scholar
  • 49 Connolly M, Nunn P. Women and tuberculosis. World Health Stat Q 1996; 49 (2) 115-119
    PubMedGoogle Scholar
  • 50 Somma D, Thomas BE, Karim F , et al. Gender and socio-cultural determinants of TB-related stigma in Bangladesh, India, Malawi and Colombia. Int J Tuberc Lung Dis 2008; 12 (7) 856-866
    PubMedGoogle Scholar
  • 51 WHO. Towards Universal Access to Diagnosis and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis by 2015. WHO Progress Report 2011. Geneva, Switzerland: WHO; 2011. . Report No.: WHO/HTM/TB/2011.3
    Google Scholar
  • 52 Zignol M, van Gemert W, Falzon D , et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ 2012; 90 (2) 111-119D
    CrossrefPubMedGoogle Scholar
  • 53 WHO. WHO Global Task Force Outlines Measures to Combat XDR-TB Worldwide. Geneva, Switzerland: WHO; 2006. . Available at: www.who.int/mediacentre/news/notes/2006/np29/ . Accessed January 18, 2013
    Google Scholar
  • 54 Velayati AA, Masjedi MR, Farnia P , et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009; 136 (2) 420-425
    CrossrefPubMedGoogle Scholar
  • 55 Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12 (5) E070517.1
    PubMedGoogle Scholar
  • 56 Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54 (4) 579-581
    CrossrefPubMedGoogle Scholar
  • 57 WHO. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, 2011 Update. Geneva, Switzerland: WHO; 2011
    Google Scholar
  • 58 Meyer-Rath G, Schnippel K, Long L , et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS ONE 2012; 7 (5) e36966
    CrossrefPubMedGoogle Scholar
  • 59 Evans CA. GeneXpert—a game-changer for tuberculosis control?. PLoS Med 2011; 8 (7) e1001064
    CrossrefPubMedGoogle Scholar
  • 60 Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 1998; 352 (9144) 1886-1891
    CrossrefPubMedGoogle Scholar
  • 61 Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005; 293 (22) 2767-2775
    CrossrefPubMedGoogle Scholar
  • 62 Lönnroth K, Castro KG, Chakaya JM , et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010; 375 (9728) 1814-1829
    CrossrefPubMedGoogle Scholar
  • 63 Raviglione M, Marais B, Floyd K , et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012; 379 (9829) 1902-1913
    CrossrefPubMedGoogle Scholar
  • 64 Lönnroth K, Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med 2008; 29 (5) 481-491
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 65 Raviglione MC, Sudre P, Rieder HL, Spinaci S, Kochi A. Secular trends of tuberculosis in western Europe. Bull World Health Organ 1993; 71 (3–4) 297-306
    PubMedGoogle Scholar
  • 66 Grzybowski S, Styblo K, Dorken E. Tuberculosis in Eskimos. Tubercle 1976; 57 (4, Suppl) S1-S58
    CrossrefPubMedGoogle Scholar
  • 67 WHO. Health Financing for Universal Coverage. Geneva, Switzerland: WHO; 2012
    Google Scholar
  • 68 Dye C, Williams BG. Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 2008; 5 (23) 653-662
    CrossrefPubMedGoogle Scholar
  • 69 Sterling TR. New approaches to the treatment of latent tuberculosis. Semin Respir Crit Care Med 2008; 29 (5) 532-541
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 70 Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004; (1) CD000171
    PubMedGoogle Scholar
  • 71 Churchyard GJ, Scano F, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007; 196 (Suppl. 01) S52-S62
    CrossrefPubMedGoogle Scholar
  • 72 Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis 2009; 13 (1) 6-16
    PubMedGoogle Scholar
  • 73 Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, Gilks CF. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005; 19 (2) 163-168
    CrossrefPubMedGoogle Scholar
  • 74 WHO and UNAIDS issue new guidance on HIV testing and counselling in health facilities, 2007. http://www.who.int/mediacentre/news/releases/2007/pr24/en/index.html . Accessed January 12, 2013
    PubMedGoogle Scholar
  • 75 Bock NN, Jensen PA, Miller B, Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis 2007; 196 (Suppl. 01) S108-S113
    CrossrefPubMedGoogle Scholar
  • 76 Wells CD, Cegielski JP, Nelson LJ , et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196 (Suppl. 01) S86-S107
    CrossrefPubMedGoogle Scholar
  • 77 WHO, ed. Global Tuberculosis Control 2009: Surveillance, Planning, Financing. Geneva, Switzerland: WHO; 2009
    Google Scholar
  • 78 Shah NS, Wright A, Bai GH , et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13 (3) 380-387
    CrossrefPubMedGoogle Scholar
  • 79 Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is “science” enough to tackle the epidemic?. EurRespir J 2007; 29 (3) 423-427
    PubMedGoogle Scholar
  • 80 Manissero D, Fernandez de la Hoz K. Surveillance methods and case definition for extensively drug resistant TB (XDR-TB) and relevance to Europe: summary update. Euro Surveill 2006; 11 (11) E061103.1
    PubMedGoogle Scholar
  • 81 Raviglione M. XDR-TB: entering the post-antibiotic era?. Int J Tuberc Lung Dis 2006; 10 (11) 1185-1187
    PubMedGoogle Scholar
  • 82 Raviglione MC, Smith IM. XDR tuberculosis—implications for global public health. N Engl J Med 2007; 356 (7) 656-659
    CrossrefPubMedGoogle Scholar
  • 83 Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis 2006; 6 (11) 710-725
    CrossrefPubMedGoogle Scholar
  • 84 Lönnroth K, Uplekar M, Arora VK , et al. Public-private mix for DOTS implementation: what makes it work?. Bull World Health Organ 2004; 82 (8) 580-586
    PubMedGoogle Scholar
  • 85 Ambe G, Lönnroth K, Dholakia Y , et al. Every provider counts: effect of a comprehensive public-private mix approach for TB control in a large metropolitan area in India. Int J Tuberc Lung Dis 2005; 9 (5) 562-568
    PubMedGoogle Scholar
  • 86 Lönnroth K, Uplekar M. Invest in breaking the barriers of public-private collaboration for improved tuberculosis care. Bull World Health Organ 2005; 83 (7) 558-559
    PubMedGoogle Scholar
  • 87 Floyd K, Arora VK, Murthy KJ , et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bull World Health Organ 2006; 84 (6) 437-445
    CrossrefPubMedGoogle Scholar
  • 88 Pantoja A, Floyd K, Unnikrishnan KP , et al. Economic evaluation of public-private mix for tuberculosis care and control, India. Part 1: Socio-economic profile and costs among tuberculosis patients. Int J Tuberc Lung Dis 2009; 13 (6) 698-704
    PubMedGoogle Scholar
  • 89 Pai M, O'Brien R. New diagnostics for latent and active tuberculosis: state of the art and future prospects. Semin Respir Crit Care Med 2008; 29 (5) 560-568
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 90 Ly LH, McMurray DN. Tuberculosis: vaccines in the pipeline. Expert Rev Vaccines 2008; 7 (5) 635-650
    CrossrefPubMedGoogle Scholar
  • 91 Lienhardt C, Raviglione M, Spigelman M , et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012; 205 (Suppl. 02) S241-S249
    CrossrefPubMedGoogle Scholar
  • 92 Nicolau I, Ling D, Tian L, Lienhardt C, Pai M. Research questions and priorities for tuberculosis: a survey of published systematic reviews and meta-analyses. PLoS ONE 2012; 7 (7) e42479
    CrossrefPubMedGoogle Scholar
  • 93 Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009; 68 (12) 2240-2246
    CrossrefPubMedGoogle Scholar
  • 94 Moreno-Serra R, Smith PC. Does progress towards universal health coverage improve population health?. Lancet 2012; 380 (9845) 917-923
    CrossrefPubMedGoogle Scholar
  • 95 Squire SB, Obasi A, Nhlema-Simwaka B. The Global Plan to Stop TB: a unique opportunity to address poverty and the Millennium Development Goals. Lancet 2006; 367 (9514) 955-957
    CrossrefPubMedGoogle Scholar
  • 96 Raviglione M, Zumla A, Marais B, Horton R, Motsoaledi A. A sustainable agenda for tuberculosis control and research. Lancet 2012; 379 (9821) 1077-1078
    CrossrefPubMedGoogle Scholar
  • 97 World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva, Switzerland: WHO; 2007
    Google Scholar
  • 98 Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006; 367 (9514) 952-955
    CrossrefPubMedGoogle Scholar